Smart cities

Houston accelerator announces newest cohort to tackle cleantech

The Ion Smart and Resilient Cities Accelerator has selected its next cohort. Courtesy of The Ion

As the world celebrated the 50th annual Earth Day on April 22, a Houston innovation organization announced a new group of startups for its accelerator program that will focus on cleantech solutions within the city of Houston and beyond.

The Ion's accelerator, which recently renewed its focus on resiliency, announced its second cohort with six startups that will create solutions for Houston's air quality, water purification, and other cleantech needs.

"Through leveraging the power of our local Ion community, The Ion Smart and Resilient Cities Accelerator is committed to solving challenges Houstonians face every day," says Christine Galib, senior director of accelerator programs at The Ion and the director of the accelerator, in a news release. "We connect participating startups with mentors, partners, and stakeholders, so they gain access to the resources they need to build, validate, and scale their technologies. Together, we are building a safer, smarter, and more accessible city for all Houstonians."

The program is supported by Intel, Microsoft, and TX/RX and has began its programming for the new cohort. The six startups selected for the program are:

  • Houston-based Eigen Control uses machine learning and chemical engineering models to combat rising CO2 emissions. Distillation process plants emit so much CO2 — and Eigen Control's processes are working to change that.
  • Houston-based Annapurna Solutions has cloud-based solutions for hazardous and solid waste management.
  • Mexico City-based S2G Energy focuses on sustainable and optimized solutions for businesses and governments with its energy-management-as-a-service technology.
  • Houston-based re:3D is a 3D-printing nonprofit that is democratizing small-scale manufacturing. Its Gigabot can use recycled and reclaimed materials for more sustainable and affordable production. The company, which has offices in Puerto Rico and Austin, donates a printer to someone making a difference with every 100 printers it sells.
  • Austin-based LifePod Corps is a nonprofit that provides disaster relief through renewable and sustainable technologies built and delivered by military veterans.
  • Houston-based Water Lens has created a real-time water data analytics platform for industries that use a lot of water — like oil and gas, agriculture, power generation, coal mining, and food processing. The technology allows for quicker, more reliable results.

The accelerator's leaders chose its theme for the cohort based on the City of Houston's Resilient Houston Strategy and Climate Action Plan. The program has identified these six startups as movers and shakers within these Smart Cities challenges.

"We are thrilled to collaborate with these startups to further develop Houston as one of America's smartest and most resilient cities," says Gabriella Rowe, executive director of The Ion, in the release. "By leveraging our resources and networks, the accelerator and Cohort 2 improve living conditions for all Houstonians. In this way, we stimulate our local economy with new jobs and economic opportunities."

Last year's inaugural cohort was announced in August and focused on resilience and mobility. After a demo day in December, the cohort continued its work in Houston through 15 pilot programs the startups had with the city. The third cohort is expected to launch toward the end of 2020, but the next theme has not yet been decided.

Trending News

Building Houston

 
 

Allterum Therapeutics Inc., a portfolio company of Fannin Innovation Studio, is using the funds to prepare for clinical trials. Photo via Getty Images

Allterum Therapeutics Inc. has built a healthy launchpad for clinical trials of an immunotherapy being developed to fight a rare form of pediatric cancer.

The Houston startup recently collected $1.8 million in seed funding through an investor group associated with Houston-based Fannin Innovation Studio, which focuses on commercializing biotech and medtech discoveries. Allterum has also brought aboard pediatric oncologist Dr. Philip Breitfeld as its chief medical officer. And the startup, a Fannin spinout, has received a $2.9 million grant from the Cancer Prevention Research Institute of Texas.

The funding and Breitfeld's expertise will help Allterum prepare for clinical trials of 4A10, a monoclonal antibody therapy for treatment of cancers that "express" the interleukin-7 receptor (IL7R) gene. These cancers include pediatric acute lymphoblastic leukemia (ALL) and some solid-tumor diseases. The U.S. Food and Drug Administration (FDA) has granted "orphan drug" and "rare pediatric disease" designations to Allterum's monoclonal antibody therapy.

If the phrase "monoclonal antibody therapy" sounds familiar, that's because the FDA has authorized emergency use of this therapy for treatment of COVID-19. In early January, the National Institute of Allergy and Infectious Diseases announced the start of a large-scale clinical trial to evaluate monoclonal antibody therapy for treatment of mild and moderate cases of COVID-19.

Fannin Innovation Studio holds exclusive licensing for Allterum's antibody therapy, developed at the National Cancer Institute. Aside from the cancer institute, Allterum's partners in advancing this technology include the Therapeutic Alliance for Children's Leukemia, Baylor College of Medicine, Texas Children's Hospital, Children's Oncology Group, and Leukemia & Lymphoma Society.

Although many pediatric patients with ALL respond well to standard chemotherapy, some patients continue to grapple with the disease. In particular, patients whose T-cell ALL has returned don't have effective standard therapies available to them. Similarly, patients with one type of B-cell ALL may not benefit from current therapies. Allterum's antibody therapy is designed to effectively treat those patients.

Later this year, Allterum plans to seek FDA approval to proceed with concurrent first- and second-phase clinical trials for its immunotherapy, says Dr. Atul Varadhachary, managing partner of Fannin Innovation Studio, and president and CEO of Allterum. The cash Allterum has on hand now will go toward pretrial work. That will include the manufacturing of the antibody therapy by Japan's Fujifilm Diosynth Biotechnologies, which operates a facility in College Station.

"The process of making a monoclonal antibody ready to give to patients is actually quite expensive," says Varadhachary, adding that Allterum will need to raise more money to carry out the clinical trials.

The global market for monoclonal antibody therapies is projected to exceed $350 billion by 2027, Fortune Business Insight says. The continued growth of these products "is expected to be a major driver of overall biopharmaceutical product sales," according to a review published last year in the Journal of Biomedical Science.

One benefit of these antibody therapies, delivered through IV-delivered infusions, is that they tend to cause fewer side effects than chemotherapy drugs, the American Cancer Society says.

"Monoclonal antibodies are laboratory-produced molecules engineered to serve as substitute antibodies that can restore, enhance or mimic the immune system's attack on cancer cells. They are designed to bind to antigens that are generally more numerous on the surface of cancer cells than healthy cells," the Mayo Clinic says.

Varadhachary says that unlike chemotherapy, monoclonal antibody therapy takes aim at specific targets. Therefore, monoclonal antibody therapy typically doesn't broadly harm healthy cells the way chemotherapy does.

Allterum's clinical trials initially will involve children with ALL, he says, but eventually will pivot to children and adults with other kinds of cancer. Varadhachary believes the initial trials may be the first cancer therapy trials to ever start with children.

"Our collaborators are excited about that because, more often than not, the cancer drugs for children are ones that were first developed for adults and then you extend them to children," he says. "We're quite pleased to be able to do something that's going to be important to children."

Trending News